Proliferative enteropathy, commonly known as “ileitis” is the most common enteric disease in pigs. Various antibiotics and vaccination strategies are used to control and treat the disease, but recent changes in regulatory policies and pressure from consumers regarding the use of antibiotics in livestock have increased the need for alternative methods to control the disease. Therefore, Elanco desires novel approaches for the prevention, treatment, or control of proliferative enteropathy in swine.
A webinar presented by Elanco and InnoCentive concerning Elanco’s Grand Challenge Program was held on October 20, 2016. A recording of the session can be accessed here.
This Theoretical Challenge requires only a written proposal.
Lawsonia intracellularis is an intracellular, bacterial pathogen known to cause proliferative enteropathy in swine. The organism infects epithelial cells and causes hyperplasia and inflammation in the small and large intestine. Although the infection is often self-limiting, sometimes pigs will develop chronic diarrhea and hemorrhagic enteritis with varying levels of severity and subsequent mortality. Antibiotic treatments have been shown to be effective in the prevention, control, and treatment of naturally occurring and clinically induced outbreaks of ileitis in pigs. However, in recent years the need to seek out alternatives to antibiotic therapy has become more relevant to the field. Therefore, Elanco desires novel approaches for the prevention, treatment, or control of proliferative enteropathy in swine.
This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on January 15, 2017.
Late submissions will not be considered.
ABOUT THE SEEKER
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for nearly 7,000 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Elanco has committed to an 8-step Antibiotic Stewardship Plan that ensures the responsible use of antibiotics, reduces shared-class antibiotic use, and replaces antibiotics with alternatives. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.com and EnoughMovement.com.
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.
What is a Theoretical-Licensing Challenge?
An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.
This Challenge is a Theoretical-Licensing Challenge, meaning that the Seeker is requesting non-exclusive rights to use the winning solution. By contrast, Theoretical-IP Transfer means that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.